Lexeo Therapeutics reports Q1 net loss $32.7M, cash $106.9M; LX2006 data positive

Lexeo Therapeutics, Inc.

2025-Q1 EPS reported -$0.99

Net loss of $32.7M ($0.99 per share) vs $21.7M ($0.77) in Q1 2024; R&D expense $17.2M, G&A $16.6M.
Cash, cash equivalents and investments of $106.9M expected to fund operations into 2027.
LX2006 in FA cardiomyopathy: interim data show 25% mean LVMI reduction and 115% avg frataxin increase; registrational study planned by early 2026.
LX2020 (PKP2-ACM): Cohort 1 showed 71% and 115% PKP2 increases; enrolling cohort 3; interim update expected H2 2025.
Redeployed $20M from non-cardiac pipeline; limited reduction in force of ~15% employees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.